Close Menu

NEW YORK – Transplant diagnostics firm CareDx reported after the close of the market on Thursday that its fourth quarter revenues rose 52 percent year over year, largely thanks to a 54 percent increase in testing revenues.

For the three months ended Dec. 31, 2019, the company reported total revenues of $35.8 million, up from $23.5 million in the fourth quarter of 2018, and in line with the Wall Street estimate.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.